Analysts Set Expectations for RARE Q1 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will post earnings of ($1.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.29) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.96) EPS.

A number of other analysts have also weighed in on RARE. Canaccord Genuity Group raised their price objective on shares of Ultragenyx Pharmaceutical from $109.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday. TD Cowen lifted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Wells Fargo & Company boosted their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, The Goldman Sachs Group upped their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $86.69.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $50.52 on Thursday. Ultragenyx Pharmaceutical has a fifty-two week low of $34.06 and a fifty-two week high of $60.37. The company’s 50 day moving average price is $55.32 and its two-hundred day moving average price is $48.11. The firm has a market capitalization of $4.66 billion, a P/E ratio of -6.92 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The company had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company’s quarterly revenue was up 42.3% on a year-over-year basis. During the same period in the prior year, the business posted ($2.23) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. UMB Bank n.a. lifted its position in shares of Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares during the last quarter. US Bancorp DE raised its holdings in shares of Ultragenyx Pharmaceutical by 5.8% in the 1st quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 390 shares in the last quarter. Arizona State Retirement System increased its holdings in Ultragenyx Pharmaceutical by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 434 shares in the last quarter. ProShare Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 8.7% during the 1st quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 486 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 506 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,556 shares of company stock worth $1,515,967 in the last three months. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.